Patient‐reported outcomes of the Treatment and Prevention Study: A real‐world community‐based trial of direct‐acting antivirals for hepatitis C among people who inject drugs

• Published in: Journal of viral hepatitis 2021-07, Vol.28 (7), p.1068-1077
• Main Authors: Goutzamanis, Stelliana, Spelman, Timothy, Harney, Brendan, Dietze, Paul, Stoove, Mark, Higgs, Peter, Thompson, Alexander, Doyle, Joseph S., Hellard, Margaret
• Format: Article
• Language: English
• Subjects: Antiviral agents; Hepatitis C; patient‐reported outcomes; people who inject drugs; Quality of life
• ISSN: 1352-0504; 1365-2893
• DOI: 10.1111/jvh.13516

The impact of hepatitis C cure with direct‐acting antivirals (DAAs) on patient‐reported outcomes (PROs) in community settings remains unclear. We aimed to assess changes in PROs over time and whether treatment was associated with sustained improved PROs in a cohort of people who inject drugs. This study is a sub‐analysis of the Treatment and Prevention Study, a nurse‐led trial where people who inject drugs and their injecting partners were recruited in a community setting, in Melbourne, Australia. Three participant groups were characterized: treatment, untreated and non‐viremic (hepatitis C RNA negative at screening). PROs included assessment of health‐related quality of life using the Short Form‐8 (SF‐8) Survey and life satisfaction using Personal Wellbeing Index (PWI). PROs were measured at baseline and every 12 weeks until week 84. Generalized estimating equations were used to measure whether treatment was associated with longitudinal PRO change. A total of 215 participants were included in this analysis. PWI scores were significantly higher at week 12 for both treatment group (p = 0.0309) and non‐viremic group (p = 0.0437) compared to baseline. However, treatment was not associated with longitudinal change in PRO scores. In conclusion, we found DAA treatment did not significantly improve PRO scores compared to those not receiving treatment and without hepatitis C. The measures used in this study may not be sensitive enough to capture the hepatitis C specific improvements in quality of life that treatment affords or factors other than treatment may be influencing quality of life scores in this cohort.